A study using RNA sequencing analysis and network pharmacology methods reported that asaxerenone, a new non-steroidal MR antagonist, targets the chemokine and phosphatidylinositol 3-kinase (PI3K)-protein kinase B (Akt) signaling pathway to facilitate therapeutic effects on DCM (Li Z. et al., 2023). The gene discussed is NR3C2; the disease is familial dilated cardiomyopathy.